DUBLIN--(BUSINESS WIRE)--Research and Markets (http://www.researchandmarkets.com/research/h6n9k7/monoclonal) has announced the addition of the "Monoclonal Antibodies Market in Gastric and Esophageal Cancers to 2019 - Crowded Late-Stage Pipelines and Favorable Market Conditions Encourage Robust Growth" report to their offering.
Gastric and esophageal cancers are two similar, overlapping groups of rare diseases, with their respective prevalence populations in the top eight markets estimated to be 392,000 and 169,000. However, their mortality rates are far higher than for other cancers, with poor prognoses even being assigned to patients diagnosed at an early stage of the disease. As such, there is a very strong unmet need for effective treatments, and so there is a strong commercial opportunity which has not yet been exploited in these indications.
A New Market Currently led by Herceptin
Due to their ability to bind to extracellular and membrane-bound molecular targets with a high degree of specificity, monoclonal Antibodies (mAbs) have represented strong clinical improvements over chemotherapies and targeted small molecule approaches in other indications such as breast and colorectal cancers. Due to certain inherent properties and favorable market conditions, these products have also been very strong commercial successes, with mAbs such as Herceptin generating $6.3 billion of revenues worldwide in 2012, and Avastin generating $6.2 billion in the same year.
One mAb, Herceptin, is currently marketed for the treatment of gastric and esophageal cancers. Although, commercially speaking, its primary indication is breast cancer, its Food and Drug Administration (FDA) approval for the treatment of gastric and esophageal cancers in 2010 is anticipated to represent a significant additional source of revenue.
Favorable Market Conditions to Drive Steady Growth Despite Weak Late-Stage Pipelines
There are currently 125 and 33 products in the pipelines for gastric and esophageal cancer respectively. Of these, there are 33 mAbs in the pipeline for gastric cancer and eight for esophageal cancer. The late-stage pipelines for these indications do include a number of novel products which have shown a reasonable degree of potential, both clinically and commercially. However, none of these products is anticipated to offer significant improvements over existing therapies. As such, their commercial potential is expected to be moderate.
The market for mAbs in gastric cancer is anticipated to grow from $256m in 2012 to $501m in 2019 at a Compound Annual Growth Rate (CAGR) of 10.0%. The market for mAbs in esophageal cancer is also anticipated to grow from $137m in 2012 to $265m in 2019 at a CAGR of 9.9%. This is due to favorable market conditions in terms of pricing structures in the US and rising disease prevalence in certain geographies and the anticipated approval of a number of late-stage pipeline drugs, particularly towards the end of the forecast period.
Key Topics Covered:
List of Tables
List of Figures
Monoclonal Antibodies Market in Gastric and Esophageal Cancers to 2019- Marketed Products
Monoclonal Antibodies Market in Gastric and Esophageal Cancers to 2019- Developmental Pipeline
Monoclonal Antibodies Market in Gastric and Esophageal Cancers to 2019- Market Forecast to 2019
Deals and Strategic Consolidations
For more information visit http://www.researchandmarkets.com/research/h6n9k7/monoclonal
About Research and Markets
Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.